Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/immunol.3.023
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Yusi Yang1, Lin Zheng2, Jianrong Li3, Baiqi Wen3,*
- 1Department of Cardiology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, 030032, China
- 2Department of Vascular Surgery, Second Hospital of Shanxi Medical University, Taiyuan 030001, China
- 3Gastroenterology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/ Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China
Corresponding Author
Baiqi Wen, baiwenqi1998@163.com
Received Date: January 04, 2024
Accepted Date: January 19, 2024
Yang Y, Zheng L, Li J, Wen B. Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and prognostic immune-associated biomarkers in breast cancer patients. J Cell Mol Immunol. 2024;3(1):1-2.
Copyright: © 2024 Yang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Effect of educational level on Alzheimer's disease-related biomarkers: Commentary
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairments that might be accompanied by declines in activities of daily living, neuropsychiatric disorders and a loss of motor function [1,2]. At present, the prevalence of dementia of Alzheimer’s type (DAT) is approximately 4% among elderly people [3]. With the increase in the aging the population, the number of individuals with DAT is still increasing.
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus. We have detected over 170 different RNA modifications, such as N6-methyladenosine (m6A), N7-methylguanosine (m7G), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N3-methylcytosine (m3C), and pseudouridine (ψ).These modifications are important for biological processes like RNA metabolism and post-transcriptional regulation.
Perspective study of UPR signaling molecules as potential biomarkers in bone metabolism
The skeletal system consists mostly of extracellular matrix and mineral salts. Osteoblasts and chondrocytes create enormous amounts of extracellular matrix proteins for skeletal systems to grow and sustain. Many skeletal metabolism related proteins are produced by endoplasmic reticulum (ER) and secrete outside cell membrane then form to extracellular oligometric matrix proteins and collagens.
Biomarkers for monoclonal antibody targeting EGFR in NSCLC: Challenges, current status, and future perspectives
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths [1]. However, significant improvements in the past decades have been achieved with improved outcomes [2-4]. Several mutations have been described as promoters of oncogenesis, and specific treatments are available, including those for Epidermal Growth Factor (EGFR) mutations [4].
Reflex ordered testing for molecular biomarkers in lung adenocarcinoma: An update
Molecular biomarker testing is essential to the work up of metastatic and advanced non-small cell lung carcinoma. Despite molecular testing guidelines proposed by the National Comprehensive Cancer Network, Association for Molecular Pathology, and many others, multiple reports continue to indicate that lung cancer patients are inadequately tested for key molecular biomarkers. Within our hospital system, reflex ordered testing of a panel of molecular biomarkers in all newly diagnosed lung adenocarcinomas was approved and implemented in 2017.